Daiichi Sankyo Presents Phase 3 ENLIVEN Study of Pexidartinib, Demonstrating Statistically Significant Clinical Improvement Across Multiple Endpoints in Patients with Tenosynovial Giant Cell Tumor at 2018 American Society of Clinical Oncology (ASCO)

- ENLIVEN, the first placebo-controlled study of a systemic investigational therapy in patients with tenosynovial giant cell tumor (TGCT), enrolled patients where surgery would be associated with potentially worsening functional limitation or severe morbidity. - Oral pexidartinib...

from PR Newswire: //https://ift.tt/2xCuu5j